Control: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Patients with Nonalcoholic Steatohepatitis

被引：0
|
作者：
Pockros, Paul J. [1 ]
Fuchs, Michael [2 ]
Freilich, Bradley L. [3 ]
Schiff, Eugene R. [4 ]
Kohli, Anita [5 ]
Lawitz, Eric J. [6 ]
Hellstern, Paul A. [7 ]
Cohen, David E. [8 ]
Owens-Grillo, Janet [9 ]
Van Biene, Courtney [9 ]
Shringarpure, Reshma [9 ]
MacConell, Leigh [9 ]
Shapiro, David A. [9 ]
机构：
[1] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92037 USA
[2] McGuire Vet Affairs Med Ctr, Richmond, VA USA
[3] Kansas City Gastroenterol & Hepatol, Kansas City, MO USA
[4] Univ Miami, Coral Gables, FL 33124 USA
[5] NIH, Bldg 10, Bethesda, MD 20892 USA
[6] Univ Texas Hlth San Antonio, Texas Liver Inst, San Antonio, TX USA
[7] Nat Coast Clin Res, Inverness, FL USA
[8] Weill Cornell Med Coll, Joan & Sanford I Weill Cornell Dept Med, New York, NY USA
[9] Intercept Pharmaceut Inc, New York, NY USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1672
引用
收藏
页码：951A / 952A
页数：2
相关论文
共 50 条
  • [1] REGENERATE: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF OBETICHOLIC ACID THERAPY FOR NONALCOHOLIC STEATOHEPATITIS
    Ratziu, V.
    Sanyal, A. J.
    MacConell, L.
    Shringarpure, R.
    Marmon, T.
    Shapiro, D.
    Younossi, Z. M.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S294 - S295
  • [2] Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis
    Younossi, Zobair M.
    Ratziu, Vlad
    Sanyal, Arun J.
    MacConell, Leigh
    Shringarpure, Reshma
    Marmon, Tonya
    Shaprio, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S1273 - S1273
  • [3] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
    Stephen A. Harrison
    Federico Perez Manghi
    William B. Smith
    Diana Alpenidze
    Diego Aizenberg
    Naomi Klarenbeek
    Chi-Yi Chen
    Eli Zuckerman
    Eric Ravussin
    Phunchai Charatcharoenwitthaya
    Pin-Nan Cheng
    Helena Katchman
    Samuel Klein
    Ziv Ben-Ari
    Anisha E. Mendonza
    Yiming Zhang
    Miljen Martic
    Shenglin Ma
    Sheena Kao
    Sandra Tanner
    Alok Pachori
    Michael K. Badman
    YanLing He
    Chinweike Ukomadu
    Eric Sicard
    Nature Medicine, 2022, 28 : 1432 - 1438
  • [4] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
    Harrison, Stephen A.
    Manghi, Federico Perez
    Smith, William B.
    Alpenidze, Diana
    Aizenberg, Diego
    Klarenbeek, Naomi
    Chen, Chi-Yi
    Zuckerman, Eli
    Ravussin, Eric
    Charatcharoenwitthaya, Phunchai
    Cheng, Pin-Nan
    Katchman, Helena
    Klein, Samuel
    Ben-Ari, Ziv
    Mendonza, Anisha E.
    Zhang, Yiming
    Martic, Miljen
    Ma, Shenglin
    Kao, Sheena
    Tanner, Sandra
    Pachori, Alok
    Badman, Michael K.
    He, YanLing
    Ukomadu, Chinweike
    Sicard, Eric
    NATURE MEDICINE, 2022, 28 (07) : 1432 - +
  • [5] CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
    Pockros, Paul J.
    Fuchs, Michael
    Freilich, Bradley
    Schiff, Eugene
    Kohli, Anita
    Lawitz, Eric J.
    Hellstern, Paul A.
    Owens-Grillo, Janet
    Van Biene, Courtney
    Shringarpure, Reshma
    MacConell, Leigh
    Shapiro, David
    Cohen, David E.
    LIVER INTERNATIONAL, 2019, 39 (11) : 2082 - 2093
  • [6] Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
    V. Ratziu
    L. de Guevara
    R. Safadi
    F. Poordad
    F. Fuster
    J. Flores-Figueroa
    M. Arrese
    Anna L. Fracanzani
    D. Ben Bashat
    K. Lackner
    T. Gorfine
    S. Kadosh
    R. Oren
    M. Halperin
    L. Hayardeny
    R. Loomba
    S. Friedman
    Arun J. Sanyal
    Nature Medicine, 2021, 27 : 1825 - 1835
  • [7] Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
    Ratziu, V.
    de Guevara, L.
    Safadi, R.
    Poordad, F.
    Fuster, F.
    Flores-Figueroa, J.
    Arrese, M.
    Fracanzani, Anna L.
    Ben Bashat, D.
    Lackner, K.
    Gorfine, T.
    Kadosh, S.
    Oren, R.
    Halperin, M.
    Hayardeny, L.
    Loomba, R.
    Friedman, S.
    Sanyal, Arun J.
    NATURE MEDICINE, 2021, 27 (10) : 1825 - +
  • [8] A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
    Ratziu, Vlad
    Sheikh, Muhammad Y.
    Sanyal, Arun J.
    Lim, Joseph K.
    Conjeevaram, Hari
    Chalasani, Naga
    Abdelmalek, Manal
    Bakken, Anezi
    Renou, Christophe
    Palmer, Melissa
    Levine, Robert A.
    Bhandari, B. Raj
    Cornpropst, Melanie
    Liang, Wei
    King, Benjamin
    Mondou, Elsa
    Rousseau, Franck S.
    McHutchison, John
    Chojkier, Mario
    HEPATOLOGY, 2012, 55 (02) : 419 - 428
  • [9] The AESOP Trial: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Obeticholic Acid in Patients with Primary Sclerosing Cholangitis
    Kowdley, Kris V.
    Bowlus, Christopher L.
    Levy, Cynthia
    Vuppalanchi, Raj
    Floreani, Annarosa
    Andreone, Pietro
    LaRusso, Nicholas F.
    Shrestha, Roshan
    Trotter, James
    Goldberg, David S.
    Rushbrook, Simon
    Hirschfield, Gideon M.
    Van Biene, Courtney
    Pencek, Richard
    MacConell, Leigh
    Shapiro, David
    HEPATOLOGY, 2017, 66 (06) : 1254A - 1255A
  • [10] THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
    Larusso, N. F.
    Bowlus, C. L.
    Levy, C.
    Vuppalanchi, R.
    Floreani, A.
    Andreone, P.
    Srestha, R.
    Trotter, J.
    Goldberg, D.
    Rushbrook, S.
    Hirschfield, G. M.
    Van Biene, C.
    Penceck, R.
    Macconell, L.
    David, S.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E67 - E67
12345